Comprehensive genomic profiling can predict response to neoadjuvant chemotherapy in triple-negative breast cancer

Background: The rate of pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC) varies, and adjuvant therapy treatment for residual cancer remains a challenge. The aim of our study was to assess the added value of FoundationOne®CDx (F1CDx) t...

Full description

Saved in:
Bibliographic Details
Main Authors: Monika Drobniene, Dominyka Breimelyte, Ieva Sadzeviciene, Rasa Sabaliauskaite, Ruta Barbora Valkiuniene, Raimundas Meskauskas, Daiva Dabkeviciene, Sonata Jarmalaite
Format: Article
Language:English
Published: Elsevier 2025-04-01
Series:Breast
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977625000426
Tags: Add Tag
No Tags, Be the first to tag this record!